Purpose: The purposes of the present study were to evaluate prognostic factors for patients with postoperative loco-regional recurrent esophageal cancer treated with chemoradiotherapy by multivariate analysis and to determine which irradiation is better, involved field irradiation or elective nodal irradiation, by matched-pair analysis. Methods: We reviewed records for 80 patients with postoperative loco-regional recurrent esophageal cancer treated by chemoradiotherapy between 2000 and 2014. The median follow-up period was 62.0 months. Thirty-one cases were treated with elective nodal irradiation and were randomly matched by risk factors to 49 cases treated with involved field irradiation (1:1). Results: Fifty-one patients had disease recurrence again, and irradiated-field failure was observed in 26 patients. The 5-year overall survival rate was 30.5% with a median survival period of 26.5 months. Grade 3 or higher late toxicity was observed in only one patient.
Introduction
Recently, neoadjuvant chemotherapy and chemoradiotherapy following surgery have resulted in favorable prognosis, but extended radical esophagectomy with two-field or three-field lymph node dissection remains a standard treatment for patients with advanced esophageal cancer. However, 30-50% of patients who have undergone a curative surgery have postoperative recurrence and there is loco-regional recurrence in about 50% of patients with postoperative recurrence (1) (2) (3) (4) (5) (6) (7) . The efficacy and safety of chemoradiotherapy for postoperative locoregional recurrent esophageal cancer have been reported, mainly from Japanese institutions including our institution (8) (9) (10) (11) (12) ; however, there has been no study showing the appropriate irradiation field in chemoradiotherapy and there have been only a few reports showing independent prognostic factors in patients with postoperative loco-regional recurrent esophageal cancer by multivariate analysis because almost all the past studies were small studies. We reviewed records for patients, including patients who were enrolled in a previous prospective trial (8) , with postoperative loco-regional recurrent esophageal cancer treated by concomitant chemoradiotherapy since 2000 in our institution. The purposes of the present study were to evaluate prognostic factors for patients with postoperative loco-regional recurrent esophageal cancer treated with chemoradiotherapy by multivariate analysis and to determine which irradiation is better, involved field irradiation or elective nodal irradiation, by matched-pair analysis.
Materials and methods
We reviewed records for all patients with postoperative locoregional recurrent esophageal cancer treated by 3D radiotherapy concomitant with chemotherapy between 2000 and 2014 in our institution and retrospectively analyzed the data. The data included data for 30 patients who were enrolled in a prospective trial of chemoradiotherapy (8) .
Eligibility criteria
The eligibility criteria included: (1) loco-regional recurrence (including para-aortic lymph node metastasis) without distant metastasis after no residual tumor (R0) resection by extended radical esophagectomy with two-field or three-field lymph node dissection, (2) no previous radiotherapy around the recurrent lesion, (3) no previous treatment before chemoradiotherapy for recurrence, (4) having undergone at least 1 cycle of concomitant chemotherapy, (5) having undergone 3D radiotherapy with more than 50 Gy, and (6) absence of another active malignant tumor during treatment.
Toxicity
Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0). An adverse effect at more than 90 days after completion of chemoradiotherapy was defined as late toxicity.
Statistics
Survival estimates were calculated using the Kaplan-Meier method from the first date of radiotherapy. Cox's regression hazard analysis using a backward stepwise selection model was used for multivariate analysis. In matched-pair analysis, cases treated with elective nodal irradiation were randomly matched by risk factors to cases treated with involved field irradiation (1:1). The survival rates of patients treated with involved field irradiation and patients treated with elective nodal irradiation were compared by the log-rank test.
A P value of less than 0.05 was considered significant. All analyses were performed using SPSS 20.0.
Ethics
The present study protocol was reviewed and approved by the ethics committee of our institution (2015-1-314).
Results
A total of 80 patients (69 males, 11 females; median age, 64.5 years; age range, 49-79 years) were enrolled. Patient characteristics are shown in Table 1 . Seventeen patients had anastomotic recurrence +/-regional lymph node metastases and 63 patients had only regional lymph node metastases. Eighteen patients had multiple regional recurrences.
All of the patients completed radiotherapy without an interval of more than 5 days and with at least 1 course of concomitant chemotherapy. Median total irradiation dose was 60 Gy (range, 50-70 Gy). The daily fractional dose of radiotherapy was 2.0 Gy, administered 5 days a week for all patients. For 31 patients, elective nodal irradiation (including the bilateral supraclavicular, mediastinal and abdominal regions) was used. For the remaining 49 patients, involved field irradiation with a margin of 1-2 cm from the macroscopic tumor was used. After 40 Gy, the field was changed in all patients to avoid the spinal cord, and only macroscopic lesions were irradiated with a margin of 1-1.5 cm. The target volume was localized for radiotherapy in all patients by CT planning. The median follow-up period for the 27 surviving patients was 62.0 months (range, 8.0-154.0 months).
The 3-and 5-year overall survival (OS) rates were 39.8% (95% confidence interval (CI) = 28.4-51.2) and 30.5% (95% CI = 19.7-41.3), respectively, with a median survival period of 26.5 months (95% CI = 21.2-31.8) (Fig. 1) . The 3-and 5-year progression-free survival rates were 28.7% (95% CI = 18.5-38.9) and 27.2% (95% CI = 17.2-37.2), respectively, and both of the 3-and 5-year irradiated-field control rates were 62.7% (95% CI = 50.9-74.5). As major late toxicity, only one patient had grade 3 or higher toxicity. One patient died 6 months after completion of the protocol due to serious pericardial effusion. The patient was enrolled in a prospective study with definitive chemoradiotherapy (8) . There was no other grade 3 or higher late toxicity. Three long-term survivors had gastric tube cancer more than 5 years after chemoradiotherapy.
In multivariate analysis, short disease-free interval (DFI) between surgery and recurrence and anastomotic recurrence were statistically significant unfavorable prognostic factors for OS (hazard ratios: 2.1 (95% CI = 1.13-3.87) and 2.5 (95% CI = 1.33-4.79), respectively) ( Table 2 ). In matched-pair analysis, patients treated with involved field irradiation were matched as shown below with patients treated with elective nodal irradiation, resulting in 26 pairs (1:1). The matching procedure was blinded to the outcome in order to avoid selection bias. Matching criteria were in the following order: DFI (≥6 months vs <6 months), pattern of recurrence (with vs without anastomotic recurrence) and number of recurrent regions (1 vs ≥2). Table 3 shows patients' characteristics after matching. OS rate in patients treated with involved field irradiation was significantly better than that in patients treated with elective nodal irradiation (5-year OS rates: 50.9% and 21.1%, respectively, P = 0.016) (Fig. 2) . Irradiated-field control rate in patients treated with involved field irradiation was significantly better than that in patients treated with elective nodal irradiation (5-year irradiated-field control rates: 79.0% and 42.2%, respectively, P = 0.014) (Fig. 3) . Metastatic recurrence in other regional lymph nodes after chemoradiotherapy occurred in one patient in the elective nodal irradiation group and in one patent in the involved field irradiation group. Distant organ metastatic recurrence occurred in four patients in the elective nodal irradiation group and in five patients in the involved field irradiation group. The patient who died 6 months after chemoradiotherapy due to serious pericardial effusion was irradiated with an elective nodal field.
Discussion
To the best of our knowledge, this is a rare report revealing prognostic factors determined by multivariate analysis in patients with postoperative loco-regional recurrent esophageal cancer treated by chemoradiotherapy. Almost of all the past studies, including our past study, were too small for multivariate analysis. Shioyama et al. reported prognostic factors determined by multivariate analysis (11); however, the study dealt with patients during the 2D radiotherapy era and 58 of the 82 patients in their study were treated without concurrent chemotherapy. The treatment method and survival results were substantially different from those today. Our analysis showed that short DFI and anastomotic recurrence have high reliability as prognostic factors after chemoradiotherapy. Although anastomotic recurrence has not been reported, DFI was sometimes reported. Hsu et al. analyzed the prognosis of 115 patients with postoperative recurrent esophageal cancer. Of those patients, although 64.4% had distant metastases, they revealed that DFI was a prognostic factor (2) . DFI was also shown to be a prognostic factor in some other studies (9, 10) . Those results are consistent with our results.
The concept of oligometastases was first proposed by Hellman et al. in 1995 (13). Niibe et al. broke down the concept of oligometastases into oligo-recurrence and sync-oligometastases (14,15). The major difference between oligo-recurrence and sync-oligometastases is the status of the primary lesion, which is the most important prognostic factor of oligometastases, and oligo-recurrence showed better prognosis than did sync-oligometastases. Furthermore, they divided oligo-recurrence into oligo-recurrence and unclassified oligometastases. Both oligo-recurrence and unclassified oligometastases were states of 1-5 metastatic tumors with a controlled primary site, but there was a difference in DFI > 6 months or not. Our results suggested that those concepts of oligorecurrence, sync-oligometastases and unclassified oligometastases are also applicable to postoperative loco-regional recurrent esophageal cancer with exclusion of distant organ metastases.
Our results were better than past results for patients with postoperative loco-regional recurrent esophageal cancer (Table 4) . Recent results are significantly better than those in reports published in the past decade (9, 10) . This might be because almost all of the patients in recent studies were treated by concurrent chemoradiotherapy and because recurrence could be detected early due to the dissemination of FDG-PET/CT. Although we have reported good results of chemoradiotherapy for solitary lymph node metastatic recurrence after curative surgery for esophageal cancer (16), concomitant chemotherapy is considered to be a key strategy even for only one metastatic recurrence. An abscopal effect or bystandar effect by radiotherapy alone may have an impact on micrometastases (17) , but such an effect is a rare and limited effect.
To the best of our knowledge, there has been no study in which the appropriate irradiation field for postoperative loco-regional recurrent esophageal cancer was evaluated. In multivariate analysis in the present study, irradiated field (involved field irradiation or elective nodal irradiation) was not included because elective nodal irradiation tended to be used in patients with 2-3 regional recurrences; however, matched-pair analysis, which was matched by DFI, pattern of recurrence and number of recurrent regions, revealed that both OS rate and irradiated-field control rate in patients treated with involved field irradiation were significantly better than those in patients treated with elective nodal irradiation. Furthermore, only one patient in the involved field irradiation group had re-recurrence in other regional lymph nodes. Our results suggest that elective nodal irradiation is not necessary in chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal cancer. We do not know why there was a significant difference in irradiatedfield control rate despite the fact that there was no difference in total irradiation dose or number of courses of chemotherapy. There are some limitations in this study. One limitation is that the ratio of patients treated with CDDP + 5-FU in the involved field irradiation group was larger than that in the elective nodal irradiation group, though the difference was not significant. However, these results suggested at least that prophylactic irradiation was not necessary for patients with postoperative loco-regional recurrent esophageal cancer when using concomitant chemotherapy. Another limitation is that this study was a retrospective study in patients treated in an institution for a long period. There might be other unaware biases.
The treatment results in the present study are good but still not satisfactory. CDDP + 5-FU remains a standard regimen as concurrent chemotherapy combined with radiotherapy for esophageal cancer. Recently, there have been some reports of CDDP + DOC or CDDP + 5-FU + DOC combined with radiotherapy for primary esophageal cancer, and the results of those studies compare favorably with the results of CDDP + 5-FU combined with radiotherapy (18, 19) . The addition of DOC to platinum-based chemoradiotherapy might improve the prognosis of patients with postoperative loco-regional recurrent esophageal cancer, and we have thus started a new prospective study for such patients (20).
The results of platinum-based chemoradiotherapy with 60 Gy are good and the treatment is safe. We did not experience any severe toxicity for the gastric tube with 60 Gy. However, because recent results of neoadjuvant chemoradiotherapy following surgery were better than results of surgery alone for primary esophageal cancer (21) , it will be difficult to perform definitive radiotherapy in patients with recurrence after neoadjuvant chemoradiotherapy following surgery. For such patients, further investigation is needed to determine whether focal therapy including radiotherapy is effective or not.
Conclusions
Short DFI and anastomotic recurrence are unfavorable factors and elective nodal irradiation is not necessary in chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal cancer. 
